Keyword: Tresiba

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

Sanofi’s Toujeo has been battling Novo's Tresiba in the basal insulin market, but new data could give it an edge in one key patient pool.

A leading position in insulin, combined with new launches like GLP1 drug Victoza, could help Novo grow to DKK19 billion in China by 2025.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Still dealing with intense pricing pressure in its key diabetes business, Novo Nordisk is embarking on its latest wave of job cuts.

Novo Nordisk is counting on multiple new drug launches—including the blockbuster-to-be semaglutide to help overcome market headwinds.

New stats show diabetes patients who suffer severe hypoglycemia are twice as likely to die. No wonder pharma's touting related data on next-gen meds.

Sanofi could push a hypoglycemia risk advantage as it works to build up Toujeo scripts—and fights off biosimilar versions of Lantus.

Novo’s combination med Xultophy, key to its growth strategy, can dampen CV risk factors such as LDL cholesterol, a new analysis showed.

While pricing challenges hit drugmakers in diabetes, Novo Nordisk CEO Lars Fruergaard Jorgensen said portfolio and execution can drive growth.